Zumilokibart
Based on 1 Customer Validation
Zumilokibart (APG-777) is an anti-IL-13 IgG1κ type humanized antibody. The recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001). Zumilokibart can be used for the research of atopic dermatitis (AD).
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 95.70%
- CAS. Nr.: 3037408-64-0
- Molecular Weight:145.082 kDa
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Biologische Aktivität
Beschreibung
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
[1]|
IL-13 |
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
IgG1-kappa
Anwendung
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized IL-13 Protein, Human (HEK293, His, HY-P70568) can bind Zumilokibart. The EC50 for this effect is 76.19 ng/mL.
Chemical Information
-
CAS. Nr. 3037408-64-0
-
Appearance Liquid
-
Molecular Weight 145.082 kDa
-
Color Colorless to light yellow
-
SMILES
N/A
-
Synonyms
APG-777
-
Versand
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
-
Data Sheet (256 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Verweise
[1]. Oliveira Dos Santos D, et al. The Role of OX40 Pathway Inhibition as a New Therapeutic Strategy for Atopic Dermatitis. BioDrugs. 2026;40(2):263-278. [Content Brief]
[2]. Babul A, et al. Biologic Monotherapies for Moderate-to-Severe Atopic Dermatitis: A Systematic Review and Bayesian Network Meta-Analysis of Established and Investigational Agents. Cureus. 2026;18(3):e105706. Published 2026 Mar 23. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Zumilokibart Related Classifications
HY-P991729 Related Classifications
Powered by Bioz